Glucagon-like peptide-1 (GLP-1) agonists have effectively helped patients lose weight and, consequently, are also changing their appearance. As a result, it’s piquing patients’ interest in facial aesthetic procedures. In a recent McKinsey survey, US medical aesthetic providers are enthusiastic about developing therapies tailored specifically to these patients, note Senior Partner Nils Peters and colleagues. Interest in combination therapies lead the pack, with 70 percent of respondents expressing excitement, followed by injectable exosomes (64 percent) and radiofrequency microneedling (52 percent).
Image description:
A series of 5 squares, each composed of 100 dots to representing percentages of respondents, show medical aesthetic providers’ excitement about select novel medical aesthetic technologies in the US. Combination therapies had 70% of respondents excited, injectable exosomes and intradermally delivered mRNA for collagen replacement therapy both had 64%, radiofrequency microneedling had 52%, and nonhyaluronic acid-based skin boosters had 51%.
Note: This image description was completed with the assistance of Writer, a gen AI tool.
Source: McKinsey US Medical Aesthetics Providers Survey, Dec 2024 (n = 174).
End of image description.
To read the article, see “GLP-1s are boosting demand for medical aesthetics,” May 15, 2025.